Drug-Coated Balloon Answers ‘Embarrassing’ Need for In-Stent Restenosis in U.S.

The 50% reductions in target lesion revascularization and target vessel myocardial infarction are “incredible” and suggest that patients may soon get “definitive therapy upfront ... reducing cost and improving care,” commented John Messenger, of the University of Colorado School of Medicine in Aurora.